Congratulations to Dr Adi Idris who has been successful in securing a National Industry PhD Program Award. PhD candidate Muskan Muskan and industry partner Gene Company, will undertake the project, Developing extracellular vesicle-based RNA therapeutics for targeting Human T cell Leukaemia Virus type 1 (HTLV-1): A solution for suppressing HTLV-1.
Dr Idris said there was no vaccine, cure or antiviral treatment for HTVL-1 driven disease, which is estimated to infect more than 20 million people worldwide, and is endemic in remote Indigenous communities in Australia.
“Our project aims to directly target HTVL-1 virus which preferentially infects a group of white blood cells of the immune system called T cells and leads to an aggressive blood cancer called adult T-cell leukaemia,” Dr Idris said.
Find out more